Platinum Compounds
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Platinum Compounds (Cisplatin) |
| FDA Approval | Yes |
| Used for | Glioblastoma |
| Clinical Trial Phase | Various, including Phase II |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Nephrotoxicity, ototoxicity, and neurotoxicity |
| OS without | Not specified |
| OS with | Not specified |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months.
From Ben Williams Book: Not specified
Loading comments...
